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Volume 6Available online 10 May 2021Background: The impact of pretreatment factors on immune checkpoint inhibition in platinum-refractory advanced
urothelial cancer (aUC) deserves further evaluation. The aim was to study the association of Bellmunt risk factors,
time from last chemotherapy (TFLC), previous therapy and PD-L1 expression with atezolizumab efficacy in platinum-
refractory aUC.
Patients and methods: This was a post-hoc analysis of patients who had received prior cisplatin or carboplatin in the
prospective, single-arm, phase IIIb SAUL study (NCT02928406). Patients were treated with 3-weekly atezolizumab 1200
mg intravenously. The primary outcome was overall survival (OS). Relationships were analysed using Cox regression and
long-rank test.
Results: Of 997 patients in SAUL, 969 were eligible for this analysis. The number of Bellmunt risk factors was associated
with OS (P < 0.001); median OS (mOS) for 0, 1 and 2-3 risk factors was 17.9, 8.9 and 3.3 months, respectively.
Significant associations were also observed between OS and TFLC (P < 0.001), programmed death-ligand 1 (PD-L1)
expression (P ¼ 0.002), and prior perioperative chemotherapy (P ¼ 0.013); mOS was 6.97 versus 11.63 months for
TFLC 6 versus >6 months, 7.75 versus 11.6 months for PD-L1 expression on <1% of tumour-infiltrating immune
cells (ICs) (IC0)/expression on 1% to <5% of tumour-infiltrating ICs (IC1) versus expression on 5% of tumour-
infiltrating ICs (IC2/3) and 10.2 versus 7.8 months for prior versus no prior perioperative chemotherapy,
respectively. The type of platinum compound and number of previous treatment lines were not associated with
outcomes.
Conclusions: Post-platinum atezolizumab is active in aUC, irrespective of previous platinum compound and lines of
therapy. Bellmunt risk stratification, PD-L1 expression, TFLC and perioperative chemotherapy were identified as
prognostic factors for OS with second-line atezolizumab, indicating the need for novel prognostic signatures for
immunotherapy-treated patients with aUC.
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- Issue 3 - 2021urothelial carcinoma (aUC).1 Since 2016, five immune
checkpoint inhibitors (ICIs) targeting programmed cell death
protein 1 (PD-1) or programmed death-ligand 1 (PD-L1)
have been approved by the United States Food and Drug
Administration and the European Medicines Agency for the
treatment of relapsed aUC based on improved survival
versus chemotherapy.2,3 Nevertheless, not all patients
benefit, with only w20% of patients achieving long-term
remission.4 Identifying those patients is becoming particu-
larly relevant since other novel agents are showing prom-
ising efficacy in patients who have failed ICI therapy andhttps://doi.org/10.1016/j.esmoop.2021.100152 1
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tients.5,6 It is, therefore, important to develop effective
selection tools for this new therapeutic paradigm.
Before the introduction of ICIs, prognosis of patients with
aUC largely depended on the first-line therapy, with those
treated with cisplatin-based combinations living longer than
those who were not.7 The impact of prior platinum therapy
on the efficacy of second-line ICI, however, has not been
studied. In addition, Eastern Cooperative Oncology Group
performance status (ECOG PS) >0, anaemia (haemoglobin
<10 g/dl) and presence of liver metastasis at the time of
initiation of second-line therapy negatively impact on overall
survival (OS), as shown by Bellmunt et al.,8 while time from
last chemotherapy (TFLC) has also been suggested as a useful
predictor.9 However, these factors have been developed
using data from patients treated with second-line chemo-
therapy and their validity among patients receiving ICIs has
not been studied. The use of biomarkers, such as PD-L1
expression or tumour mutational burden (TMB), has also
been shown to hold promise as factors predicting benefit to
ICIs.10,11 Importantly, these data have been largely derived
from cohorts from clinical trials.
Atezolizumab is a PD-L1 inhibitor approved for first-line
treatment of aUC in platinum-ineligible patients and
cisplatin-ineligible patients whose tumours have high PD-L1
expression (5%). It is also indicated after first-line plat-
inum-based chemotherapy based on improved outcomes in
clinical trials.10-13 The prospective phase IIIb SAUL study
(N ¼ 997) of atezolizumab in relapsed aUC reported the
largest ‘real-world’ series in this setting.14 SAUL represents
the ideal platform to study prognostic factors in ICI second-
line therapy since it more accurately reflects everyday
practice than interventional, randomised trials, while also
including the PD-L1 status of the majority of patients.
Importantly, the study included difficult-to-treat pop-
ulations, such as non-urothelial carcinomas and patients
with autoimmune diseases, which are underrepresented in
clinical trials but frequently present in everyday practice,
yet relevant clinical evidence is lacking. Therefore, we used
the SAUL database to investigate the prognostic value of
patient-related characteristics, factors related to previous
chemotherapy as well as PD-L1 expression among patients




De-identified data including demographic, clinicopathologic,
laboratory and outcomes from the complete SAUL database
were provided by the sponsor. The data cut-off for the
primary analysis was 16 September 2018. The database was
not updated for this analysis. All patients provided written
informed consent and the trial was approved by the insti-
tutional review board or ethics committee at each site
before study start.
Inclusion criteria have been previously published.14
Briefly, SAUL (NCT02928406) is a single-arm, phase IIIb2 https://doi.org/10.1016/j.esmoop.2021.100152safety and efficacy study of atezolizumab in locally
advanced or metastatic urothelial or non-urothelial carci-
noma of the urinary tract. All patients were required to
have ECOG PS 2 and disease progression during or
following one to three prior treatments for inoperable,
locally advanced or metastatic disease. Patients with
relapse within 12 months of perioperative (neoadjuvant or
adjuvant) platinum-based chemotherapy, without any other
line of chemotherapy for advanced/metastatic disease,
were also eligible. Patients with treated central nervous
system (CNS) metastases, autoimmune disease, concomi-
tant corticosteroids or renal impairment were eligible. Pa-
tients were excluded from the current substudy if they had
not received prior cisplatin or carboplatin.
Intervention
Patients received atezolizumab 1200 mg intravenously
every 3 weeks until loss of clinical benefit, unacceptable
toxicity, the patient’s or investigator’s decision to discon-
tinue therapy or death. Tumours were assessed every 9
weeks for the first year and then every 12 weeks until
confirmed disease progression. After atezolizumab discon-
tinuation, patients were followed for disease progression
and OS for up to 4 years after enrolment of the last patient.
Outcomes
The primary endpoint of this substudy was OS. Secondary
endpoints were investigator-assessed progression-free sur-
vival (PFS) RECIST version 1.1 and objective response rate
(ORR, complete/partial response) assessed by RECIST
version 1.1 and modified RECIST. Immunohistochemical
staining of PD-L1 expression was carried out on formalin-
fixed, paraffin-embedded tissues using VENTANA SP142
rabbit monoclonal antibody (Ventana BenchMark ULTRA
reader).15
Statistical analysis
All time-to-event data (OS, PFS) were calculated from day 1,
cycle 1 of study treatment and were summarised using
KaplaneMeier estimates and medians reported with cor-
responding 95% confidence intervals (CIs). TFLC was calcu-
lated from the last day of the last chemotherapy line
administered before study entry on day 1, cycle 1 of study
treatment. Post-hoc subgroup analyses of efficacy according
to the following factors were carried out: previous platinum
compound (cisplatin versus carboplatin; patients who
received both were categorised in the cisplatin group),
number of previous lines of systemic therapy (0 versus 1),
TFLC (cut-off points at 3, 6, 9 and 12 months), PD-L1
expression [tumour-infiltrating immune cell (IC) score of
0/1 versus 2/3], baseline haemoglobin (<10 versus 10 g/
dl), liver metastases (yes versus no), ECOG PS (0 versus 1/2),
number of Bellmunt risk factors (0 versus 1 versus 2/3) and
adjuvant or neoadjuvant therapy (yes versus no). Associa-
tions [hazard ratio (HR) and 95% CI] of each of these factors
with OS and PFS were evaluated using Cox proportional
hazards model and survival was compared using theVolume 6 - Issue 3 - 2021



























0 prior linesc 144 (15)
1 prior linesc 33 (3)
Adjuvant 272 (28)
0 prior linesc 214 (22)
1 prior linesc 58 (6)
Both 14 (1)
0 prior linesc 11 (1)
1 prior linesc 3 (<1)
Histological type, n (%)
Urothelial 924 (95)
Non-urothelial/mixed 45 (5)
Squamous neoplasms 18 (2)
Glandular neoplasms 6 (<1)
Neuroendocrine tumours 7 (<1)
Bellini collecting duct 8 (<1)
Missing 6 (<1)
Haemoglobin, n (%)
<10 g/dl 152 (16)
10 g/dl 794 (82)
Missing 23 (2)










Prior platinum compound, n (%)
Cisplatin 581 (60)
Carboplatin 388 (40)
Primary tumour location, n (%)
Bladder 724 (75)




Time since last therapy, n (%)
3 months 353 (36)
>3 months 616 (64)
6 months 593 (61)





9 months 765 (79)
>9 months 204 (21)
Percentages may not add to 100% due to rounding.
ECOG PS, Eastern Cooperative Oncology Group performance status; ICs, immune
cells; IQR, interquartile range; PD-L1, programmed death-ligand 1.
a Missing: n ¼ 2.
b IC0, expression on <1% of tumour-infiltrating ICs; IC1, expression on 1% to <5% of
tumour-infiltrating ICs; IC2/3, expression on 5% of tumour-infiltrating ICs.
c Lines for advanced/metastatic disease before study treatment.
d Bellmunt risk factors: ECOG performance status 1, haemoglobin <10 g/dl and
presence of liver metastasis.8
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Pearson’s chi-squared test. To assess if the magnitude of the
changes of survival due to each of the above factors depend
on the other factors also studied, we included interaction
terms in the Cox model. All tests were two-sided with a cut-
off for statistical significance of P < 0.05.
Additional exploratory analysis of the importance of the
prespecified factors on OS was carried out exclusively in two
groups with special clinical interest: non-urothelial/mixed
and human immunodeficiency virus (HIV)/autoimmune
disease/steroid treatment populations. Since 148 patients
received post-study anticancer therapies, we also carried
out exploratory analysis of the impact of administration of
post-study therapy on the prognostic significance of the
prespecified factors.RESULTS
Of 997 patients treated with atezolizumab in SAUL, 975
had received prior platinum treatment (Supplementary
Figure S1, available at https://doi.org/10.1016/j.esmoop.
2021.100152). Of those, 6 patients who either had
missing information on type of platinum treatment (n ¼ 3)
or had oxaliplatin (n ¼ 3) were excluded, leaving 969 pa-
tients who were included in this substudy. Table 1 sum-
marises baseline characteristics relevant for this analysis.
Most patients received atezolizumab immediately after
first-line platinum failure (55%). A substantial number of
patients (38%) received atezolizumab following progression
within 12 months after neoadjuvant or adjuvant chemo-
therapy, i.e. as first-line therapy for advanced/metastatic
disease, while only 7% of patients had received 2 lines of
therapy before enrolment. Of the 600 patients who had
received previous lines of chemotherapy for advanced/
metastatic disease, 94 (16%) had received perioperative
chemotherapy. Among the 969 patients, 100 had ECOG PS
of 2, 45 had non-urothelial histology, 14 had CNS disease, 2
were HIV positive, 34 had a history of autoimmune disease
and 38 were on steroid treatment at study entry. One
hundred and forty-eight patients (15%) received some form
of anticancer therapy after atezolizumab (Supplementary
Table S1, available at https://doi.org/10.1016/j.esmoop.
2021.100152). No patient received erdafitinib or enfortu-
mab vedotin.https://doi.org/10.1016/j.esmoop.2021.100152 3
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months (95% CI: 11.8-13.3), 539 (55.6%) patients had died,
492 (91.3%) due to urothelial cancer, while 212 (21.9%)
were still on study treatment. Median OS for the cohort
included in the current analysis was 8.6 months (95% CI:
7.6-9.7), the median PFS was 2.2 months (95% CI: 2.1-2.4)
and ORR was 13.3%.OS by Bellmunt risk stratification
Risk stratification according to the number of Bellmunt risk
factors resulted in significant (P < 0.001) and clinically
meaningful differences in prognosis: patients with no risk
factors had a median OS of 17.9 months [95% CI: 12.7 to
not reached (NR)], those with one factor had an OS of 8.9
months (95% CI: 7.5-10.9) and two-to-three factors 3.3
months (95% CI: 2.7-4) (Figure 1A, Table 2). Each of the
factors was individually associated with OS.Worse ECOG PS,
haemoglobin <10 g/dl and presence of liver metastases
were predictors of shorter median OS (Supplementary
Figure S2A-C, available at https://doi.org/10.1016/j.
esmoop.2021.100152).OS by previous therapy
Prior cisplatin-based chemotherapy was associated with a
numerically longer median OS compared with carboplatin-
based chemotherapy [9.4 months (95% CI: 8.1-10.9)
versus 7.5 months (95% CI: 6.4-9.2)] but the difference did
not reach statistical significance (P ¼ 0.056; Figure 1B,
Table 2). To evaluate whether this numerical difference was
influenced by other factors (ECOG PS, haemoglobin <10 g/
dl, liver metastasis, TFLC, PD-L1 expression, lines of previous
therapy and perioperative chemotherapy), we carried out
an exploratory analysis using Pearson’s chi-square, t-test
and other similar tests to assess if the distribution of these
factors differed between the cisplatin/carboplatin groups.
Cisplatin-based chemotherapy was associated with three
favourable prognostic factors: no liver metastasis (75%
versus 69%, P ¼ 0.044), longer median TFLC (7.2 versus 5.4
months, P < 0.001) and prior perioperative chemotherapy
(56% versus 35%, P < 0.001) versus carboplatin-based
therapy. Including liver metastasis, TFLC and perioperative
therapy as stratification factors in a log-rank test, we
confirmed that there was no significant association be-
tween the type of previous platinum therapy and OS (P ¼
0.731). There was no association between OS and the
number of previous lines of therapy (P ¼ 0.232; Figure 1C,
Table 2).
The administration of prior perioperative chemotherapy
(neoadjuvant or adjuvant or both) was significantly associ-
ated with prolonged OS (P ¼ 0.013; Figure 2A, Table 2). The
median OS was 10.2 months (95% CI: 8.3-12.4) for periop-
erative chemotherapy versus 7.8 months (95% CI: 6.6-9) for
none. After excluding the 369 patients who had received
perioperative chemotherapy as their only therapy before
atezolizumab, a significant difference in median OS in
favour of perioperative chemotherapy was still observed:4 https://doi.org/10.1016/j.esmoop.2021.10015212.5 (95% CI: 8-NR) versus 7.8 months (95% CI: 6.6-9)
(P ¼ 0.011; Figure 2B).OS by TFLC
There was a significant association between TFLC and OS
(P < 0.001; Figure 3A, Table 2). This was observed for
all time periods studied (Supplementary Figure S3A-D,
available at https://doi.org/10.1016/j.esmoop.2021.100152)
with longer TFLC associated with longer OS. The sharpest
difference in median OS was observed at the 6-month cut-
off point [6.97 (95% CI: 5.88-7.95) versus 11.63 months
(95% CI: 9.99-17.97)], which was therefore used as a cut-off
point for a dichotomised interaction analysis with other
factors included in this analysis. An interaction was identi-
fied between TFLC and the number of previous lines of
therapy (P ¼ 0.034) where TFLC >6 months was a positive
prognostic factor for those patients who had received 1
previous line of systemic therapy for advanced/metastatic
disease (HR 0.53; 95% CI: 0.41-0.68); in contrast, no asso-
ciation was found for patients who had not received prior
chemotherapy for aUC (Figure 3B).OS by PD-L1 expression
A PD-L1 IC score of 2/3 was significantly associated with
prolonged OS (P ¼ 0.002) with a median OS of 11.6 months
(95% CI: 8.8-18.8) versus 7.75 months (95% CI: 6.5-9) in
tumours with IC 0/1 (Figure 3C, Table 2). A similar benefit
by high PD-L1 expression was observed across all subgroups
analysed (Supplementary Figure S4, available at https://doi.
org/10.1016/j.esmoop.2021.100152).Other analyses
Fewer Bellmunt risk factors, stronger PD-L1 expression and
longer TFLC were each significantly associated with pro-
longation of PFS (each P < 0.001) and higher ORR (each P <
0.001) (Table 2). ECOG PS 0, haemoglobin >10 g/dl and the
absence of liver metastasis were each associated with
longer PFS while only ECOG PS 0 and absence of liver
metastasis were associated with higher ORR with similar
results for ORR by modified RECIST (data not shown).
Exploratory analyses of the significance of the studied
factors in non-urothelial/mixed tumours (n ¼ 45), HIV/
autoimmune disease/steroid therapy (n ¼ 72) and accord-
ing to the administration of post-study therapy yielded
generally similar results to those of the whole population
(Supplementary Tables S2 and S3, available at https://doi.
org/10.1016/j.esmoop.2021.100152). Nevertheless, the
power of these analyses is limited due to the low number of
patients in each subgroup.
DISCUSSION
To our knowledge, this is the largest study to assess the
impact of pretreatment factors on ICI efficacy outcomes in
patients with aUC. The strengths of this study include uti-
lization of ‘real-world’ but prospectively collected data,




















265 132(122) 75(51) 38(22) 16(7) 6(3) 1(0) 0(0)2/3
383 298(73) 208(69) 138(37) 89(18) 51(7) 7(1) 0(1)1
296 281(13) 227(41) 163(27) 105(24) 56(10) 9(2) 0(1)0
Number at risk























388 278(101) 199(64) 127(35) 75(20) 38(6) 7(1) 0(1)Carbo-based
581 448(114) 323(98) 219(52) 137(30) 75(14) 10(2) 0(1)Cis-based
Number at risk






















600 448(135) 323(102) 203(58) 117(32) 62(12) 9(1) 0(0)≥1
369 278(80) 199(60) 143(29) 95(18) 51(8) 8(2) 0(2)0
Number at risk







Figure 1. OS with atezolizumab according to (A) the number of Bellmunt risk factorsa, (B) the type of previous platinum therapy (cisplatin versus carboplatin) and
(C) the number of previous lines of therapy (0 versus ‡1; N [ 969).8
Carbo, carboplatin; Cis, cisplatin; ECOG, Eastern Cooperative Oncology Group; OS, overall survival.
a Bellmunt risk factors: ECOG performance status 1, haemoglobin <10 g/dl and presence of liver metastasis.
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Table 2. Median OS, PFS and ORRs according to subgroups
n Median OS
(95% CI)
P HR (95% CI) Median PFS
(95% CI)
P HR (95% CI) ORRa (%) P
Bellmunt risk factorsb <0.001 <0.001 <0.001
0 296 17.9 (12.7-NR) 1 4.1 (3.5-4.4) 1 19
1 383 8.9 (7.5-10.9) 1.8 (1.4-2.2) 2.3 (2.1-2.8) 1.3 (1.1-1.6) 14
2-3 265 3.3 (2.7-4) 4.3 (3.4-5.4) 2 (1.9-2.1) 2.3 (1.9-2.8) 7
Previous therapy 0.056 0.162 0.095
Cisplatin-based 581 9.4 (8.1-10.9) 1 2.3 (2.1-2.5) 1 15
Carboplatin-based 388 7.5 (6.4-9.2) 1.2 (0.9-1.4) 2.2 (2.1-2.4) 1.1 (0.9-1.3) 11
Previous lines 0.232 0.394 0.084
0 369 9.7 (7.5-11.9) 1 2.2 (2.1-2.9) 1 16
1-3 600 8.3 (7.2-9.4) 1.1 (0.9-1.3) 2.2 (2.1-2.4) 1.1 (0.9-1.2) 12
PD-L1 expressionc 0.002 <0.001 <0.001
IC0-1 647 7.75 (6.5-9) 1 2.1 (2.1-2.3) 1 10
IC2-3 257 11.6 (8.8-18.8) 0.7 (0.6-0.9) 2.6 (2.1-4.1) 0.8 (0.6-0.9) 21
TFLC (months) <0.001 <0.001 <0.001
0-3 353 6.7 (5.4-7.8) 1 2.1 (2.1-2.2) 1 8
3-6 240 7.5 (5.7-9.9) 0.9 (0.7-1.1) 2.1 (2.1-2.3) 0.9 (0.8-1.8) 12
6-9 172 10.6 (8.4-18) 0.7 (0.5-0.9) 2.5 (2.2-4.1) 0.7 (0.6-0.9) 19
9-12 96 NR (9.9-NR) 0.5 (0.3-0.7) 4.8 (2.5-6.5) 0.6 (0.4-0.8) 24
>12 108 11 (7.75-NR) 0.6 (0.5-0.8) 3.7 (2.2-4.2) 0.7 (0.6-0.9) 15
Neoadjuvant/adjuvant 0.013 0.139 0.077
No 506 7.8 (6.6-9) 1 2.2 (2.1-2.3) 1 11
Yes 463 10.2 (8.3-12.4) 0.8 (0.7-0.9) 2.3 (2.1-3.2) 0.9 (0.8-1.04) 15
CI, confidence interval; HR, hazard ratio; IC, immune cell; NR, not reached; ORR, objective response rates; OS, overall survival; PD-L1, programmed death-ligand 1; PFS,
progression-free survival; TFLC, time from last chemotherapy.
a ORR by RECIST version 1.1.
b Bellmunt risk factors: ECOG performance status 1, haemoglobin <10 g/dl and presence of liver metastasis.8
c IC0, expression on <1% of tumour-infiltrating ICs; IC1, expression on 1% to <5% of tumour-infiltrating ICs; IC2/3, expression on 5% of tumour-infiltrating ICs.
ESMO Open A. Bamias et al.cohort sample size. This cohort closely resembles everyday
practice since it includes ‘trial-ineligible’ patients, such as
patients with poor performance status, poor renal function,
CNS metastases, non-urothelial histology, autoimmune dis-
eases and steroid treatment.
The validity of the Bellmunt prognostic factors are well
established in patients treated with second-line chemo-
therapy for aUC. To our knowledge, this is the first study to
statistically evaluate the prognostic value of these factors
following a second-line ICI. We found that all factors, as well
as the respective risk stratification, were associated with
prognosis. Nevertheless, our results suggest that other
factors may be useful in this respect.
Atezolizumab was equally effective following treatment
with cisplatin and carboplatin which is of importance for the
carboplatin group due to its high unmet need for effective
treatment options. In contrast, we demonstrated that TFLC
was an important determinant of atezolizumab efficacy and
a potentially useful selection criterion. An interval of <6
months was associated with a median OS of only 6.97
months in contrast with 11.63 for >6 months, thereby
clearly identifying a cohort in need of more effective ther-
apies. The reasons for this association are unclear but
similar findings have been described with non-ICIs,9 indi-
cating that TFLC may reflect a pragmatic measure of a fairly
low pace of disease. Nevertheless, other factors may also
play a role. Recent data from the IMvigor130 randomised
study showed similar response rates for the combination of
chemotherapy with atezolizumab versus chemotherapy
alone, suggesting that chemotherapy and atezolizumab may
benefit similar patient populations.13 Thus, patients who6 https://doi.org/10.1016/j.esmoop.2021.100152remain on long remission from chemotherapy may have a
better chance of response to subsequent ICI.
The association of perioperative chemotherapy with
improved OS has to our knowledge not been reported
before. In this group of patients, the disease would have
initially been diagnosed at a localised state, which may
imply a less aggressive course than in de novo metastatic
disease. Biological factors may also explain these findings.
Neoadjuvant chemotherapy has been shown to affect im-
mune elements in the tumour microenvironment,16 which
may potentiate the effect of subsequent ICI therapy.17,18
We also found that TFLC was associated with prolonged
survival only in the population that had received 1 line of
previous chemotherapy for aUC. This may be due to the fact
that patients with only prior perioperative chemotherapy
had relapsed within 12 months of treatment, thus excluding
patients with longer treatment-free interval.
In concert with previous reports,19,20 we found no impact
of the number of previous lines of therapy on the efficacy
of atezolizumab. Admittedly, only 7.1% of our patients
received 2-3 previous lines of therapy, which reduces the
power of the analysis for this subgroup. Nevertheless, given
the convincing benefit of ICIs and the existing guidelines,2,21
it is unlikely that patients will be treated with many lines of
therapy before exposure to ICIs. Furthermore, in two other
studies, which included patients receiving up to five lines of
previous therapies, albeit in small numbers, heavily
pretreated patients did not experience reduced efficacy of
ICIs.19,20
The percentage of high PD-L1 expressing (IC2/3) tu-




















463 351(98) 257(70) 180(37) 118(21) 64(10) 9(2) 0(2)yes
506 375(117) 265(92) 166(50) 94(29) 49(10) 8(1) 0(0)no
Number at risk























94 73(18) 58(10) 37(8) 23(3) 13(2) 1(0) 0(0)yes
506 375(117) 265(92) 166(50) 94(29) 49(10) 8(1) 0(0)no
Number at risk






Figure 2. OS with atezolizumab according to prior perioperative (none versus adjuvant or neoadjuvant) chemotherapy for (A) the whole cohort (N [ 969) and (B)
patients with prior therapy for advanced/metastatic disease (N [ 600).
OS, overall survival.
A. Bamias et al. ESMO Openmonths) within the IC2/3 subgroup were in line with those
reported in the IMvigor210 (32.2%, 26%, 11.4 months,
respectively) and IMvigor211 (24.8%, 23%, 11.1 months,
respectively) trials,10,12 confirming the efficacy of atezoli-
zumab in this patient group. We found a strong associa-
tion of IC2/3 with response to atezolizumab: ORR was
almost doubled compared with IC0/1. Similar convincing
trends in OS and PFS were observed. Currently, PD-L1
expression is used only for the selection of cisplatin-
ineligible patients to receive first-line ICIs, while no
selection is recommended in the second-line setting.2,22
Nevertheless, recent developments in other non-
immunotherapy targeted therapies in post-first-line aUC,
such as antibody-drug conjugates, will accelerate interest
in the potential role of biomarkers. PD-L1 may be useful,
especially since recent data suggest that its combination
with other markers, such as TMB or molecularVolume 6 - Issue 3 - 2021classification, may be more accurate tools to predict
benefit from modern immunotherapy.23
Limitations of our study include the post-hoc nature of
the analyses and the small sample size in some subgroups
which limits the interpretation of those results and may
have contributed to the large range for some 95% CIs.
Further confirmatory analyses in larger patient populations
are needed to validate these results.
This SAUL substudy identified factors for the selection of
patients with aUC who were likely to derive a significant
benefit from atezolizumab in the post-chemotherapy
setting, while it may act as a ‘benchmark’ for efficacy
assessment in single-arm phase II trials. Further research
should focus on the development of prognostic signatures
that would separate patients treated with immunotherapy
into distinct prognostic groups, in accordance with findings
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Figure 3. (A) OS with atezolizumab according to TFLC; (B) forest plot of OS depicting subgroup analysis and tests for interaction according to TFLC dichotomised at
the 6-month cut-off point (N [ 969); (C) OS with atezolizumab according to PD-L1 expression (IC0/1 versus IC2/3).
Carbo, carboplatin; CI, confidence interval; Cis, cisplatin; HGB, haemoglobin; HR, hazard ratio; IC0, expression on <1% of tumour-infiltrating immune cells; IC1, expression on 1% to
<5% of tumour-infiltrating immune cells; IC2/3, expression on 5% of tumour-infiltrating immune cells; OS, overall survival; PD-L1, programmed death-ligand 1; PS, performance
status (Eastern Cooperative Oncology Group); TFLC, time from last chemotherapy.
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